The use of Generative AI to accelerate antibody drug development for novel therapeutic targets
Despite the fact that the clinical effectiveness of antibody-based therapies has been established there are no methods available for the design of antibodies from scratch with wet laboratory validation.
In a recent study published on the bioRxiv* server, generative AI models were used to create de novo designed antibodies against three different targets in a zero shot fashion. Zero-shot design involves creating an antibody that binds to an antigen, without further optimization. De novo is the term used to describe the newly designed process, which means that proteins (antibodies were designed from scratch or from first principles).